Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
PBLA Panbela Therapeutics
0.133
+0.013+10.83%
Post Mkt Price
0.1330.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
63.94% 3.62M 856.24% 21.29M 78.11% 4M 73.97% 10.01M
Selling and administrative expenses
40.04% 1.29M 1.37% 1.26M 56.31% 1.8M 41.18% 4.59M
-General and administrative expense
40.04% 1.29M 1.37% 1.26M 56.31% 1.8M 41.18% 4.59M
Research and development costs
81.10% 2.33M 1,933.30% 20.03M 100.91% 2.21M 116.49% 5.42M
Operating profit
-63.94% -3.62M -856.24% -21.29M -78.11% -4M -73.97% -10.01M
Net non-operating interest income expense
-8,000.00% -81K -250.00% -14K 33.33% -2K 35.29% -11K
Non-operating interest income
500.00% 6K -- 2K -- 1K -- --
Non-operating interest expense
4,250.00% 87K 300.00% 16K 0.00% 3K -35.29% 11K
Other net income (expense)
-125.07% -754K -472.97% -848K 354.92% 311K -185.03% -602K
Special income (charges)
-- -- -- -- -- -- -- 0
Other non- operating income (expenses)
-125.07% -754K -472.97% -848K 354.92% 311K -199.50% -602K
Income before tax
-75.10% -4.46M -831.37% -22.15M -55.71% -3.7M -109.82% -10.62M
Income tax
86.14% -56K 90.63% -18K 75.00% -29K -65.42% -488K
Net income
-105.51% -4.4M -912.35% -22.13M -62.43% -3.67M -112.56% -10.14M
Net income continuous Operations
-105.51% -4.4M -912.35% -22.13M -62.43% -3.67M -112.56% -10.14M
Minority interest income
Net income attributable to the parent company
-105.51% -4.4M -912.35% -22.13M -62.43% -3.67M -112.56% -10.14M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-105.51% -4.4M -912.35% -22.13M -62.43% -3.67M -112.56% -10.14M
Basic earnings per share
-31.25% -0.21 -586.36% -1.51 -17.39% -0.27 -40.32% -0.87
Diluted earnings per share
-31.25% -0.21 -586.36% -1.51 -17.39% -0.27 -40.32% -0.87
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
CEO: Dr. Jennifer K Simpson, PhD
Market: NASDAQ
Listing Date: 08/28/2020
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist